Top 10 Regional Bank Stocks To Buy For 2015

After rising 67% in the past 52-weeks, it is understandable that the price targets for First Financial Bankshares (FFIN) are slightly under the bank's current market price of $57.69 per share. But, the premium paid for these shares appear to be warranted.

First Financial is one of the fastest growing regional banks in Texas (though all appear to be very fast growing) but it is one that has a very unique strategy that I believe gives the bank a competitive advantage that isn't found in most of the its regional peers.

I'm timid of the current market valuation of FFIN because it is getting a premium well above the industry average but, the bank is setting up for long-term growth and isn't showing any signs of slowing down anytime soon. With that said, below I have outlined why I like First Financial's strategy and financial position, followed by a review of the company's current valuation.

Strategy

A lot of times we see a growing regional bank increase deposit share and assets by purchasing other regionals in an area where they are weak and need more exposure. This makes sense for obvious reasons but other than increased visibility and access to the local markets, investors rarely understand why that particular location was chosen for growth over any of the other areas the bank occupies. With First Financial, this is absolutely not an issue and, to be honest, I'm extremely surprised that any bank in Texas has been able to dominate any area as much as FFIN has.

Hot Small Cap Stocks To Watch Right Now: Juno Therapeutics Inc (JUNO)

Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell.

To provide treatment, the Company harvests blood cells from a cancer patient, separate the appropriate T cells, activate the cells, insert the gene sequence for the CAR or TCR construct into the cells��Deoxyribonucleic Acid (DNA), and grow these modified T cells to the desired dose level. The modified T cells can then be infused into the patient or frozen and stored for later infusion. Once infused, the T cells are designed to multiply, through a process known as cell expansion, when they encounter the targeted proteins and to kill the targeted cancer cells.

CD19-Directed Product Candidates

The Company�� product candidates, such as JCAR015, JCAR017, and JCAR014, which use CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. The Company has rights to commercialize each of these product candidates across the world. The Company�� JCAR015 is an advanced development product candidate, and it has demonstrated clinically meaningful complete remission rates in adult patients with r/r ALL. JCAR015 uses the CD28 costimulatory domain and CD3 enriched peripheral blood mononuclear cells (PBMC), which requires fewer process steps for! manufacture than its defined cell composition product candidates. JCAR015 is being tested in a Phase I open label clinical trial of patients with r/r ALL for the treatment of refractory chronic lymphocytic leukemia.

JCAR017 also targets CD19, but differs from JCAR015 in several important respects. JCAR017 uses the 4-1BB costimulatory domain and a defined cell composition of CD4+ T cells and CD8+ T cells. JCAR017 is in development for pediatric patients with r/r ALL. JCAR017 is being evaluated in a Phase I/II clinical trial in pediatric r/r ALL.

JCAR014 also targets CD19. JCAR014 uses the 4-1BB costimulatory domain and is composed of CD8+ central memory T cells and CD4+ T cells in a defined ratio. JCAR014 is being evaluated in a Phase I/II trial as a treatment for a number of B cell malignancies in patients relapsed or refractory to standard therapies.

Additional Product Candidates

The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers not targeted by CD19-directed products, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung, and pancreatic cancers, as well as B cell malignancies that do not express CD19. The Company�� CD22 is a cell surface protein widely expressed on B lymphocytes. It is expressed by B cell malignancies, including non-Hodgkin�� lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The Company�� L1CAM, also known as CD171, is a cell-surface adhesion molecule that plays an important role in the development of a normal nervous system. It is overexpressed in neuroblastoma, and there is increasing evidence of aberrant expression in a variety of solid organ tumors, including glioblastoma and lung, pancreatic, and ovarian cancers.

The Company�� MUC-16 is a protein overexpressed in the ovarian cancers, but not on the surface of normal ovary cells. CA-125 is a protein found in the ! blood of ! ovarian cancer patients that results from the cleavage of MUC-16. CA-125 levels in the blood are a common test for ovarian cancer progression because they correlate with cancer progression. Its MUC-16/IL-12 product candidate uses its armored CAR technology. IL-12 is a cytokine that can help overcome the inhibitory effects that the tumor micro-environment can have on T cell activity.

The Company�� ROR-1 is a protein expressed in the formation of embryos, but in normal adult cells its surface expression is predominantly found at low levels on adipocytes, or fat cells, and briefly on precursors to B cells, or pre-B cells, during normal B cell maturation. ROR-1 is overexpressed on a variety of cancers including a subset of non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, and prostate cancer. It is expressed on B cell chronic lymphocytic leukemia and mantle cell lymphoma. The Company�� high-affinity TCR T cell product candidate targets WT-1, an intracellular protein that is overexpressed in a number of cancers, including adult myeloid leukemia, or AML, and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.

Advisors' Opinion:

• [By John Udovich]

  Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.

Top 10 Regional Bank Stocks To Buy For 2015: Reed Elsevier NV (ENL)

Reed Elsevier NV offers professional information solutions in North America and Europe. The company�s Scientific, Technical & Medical segment publishes research, reference, and education content; and offers database and workflow solutions for scientists, research leaders and administrators, doctors, nurses, health professionals, and students, as well as hospitals, academic and research institutions, health insurers, managed healthcare organizations, research corporations, and governments. It also provides abstract and citation database of research literature; an oil and gas exploration tool that packages research-relevant geological content and tags that content to enable search functionality; and solutions for synthetic chemists. In addition, this segment offers software and tools that enhance research outcomes of academic institutions and researchers; and Web-based tools for the engineering community. Its Risk Solutions segment provides data and analytics to property an d casualty personal and commercial, and life insurance carriers; and risk and identity management, fraud detection, credit risk management, and compliance solutions for financial institutions, as well as offers risk-related information to the legal industry. The company�s Business Information segment provides data services, such as information and pricing services for the chemicals, fertilizers, and energy sectors; payment routing data and anti-money laundering services, as well as compliance information to the banking and corporate sectors; online regulatory guidance, practices, and tools for HR professionals; and online construction data and information to the construction industry. Its Legal segment offers legal, regulatory, news and business, and analysis services to legal, corporate, government, and academic customers. The company�s Exhibitions segment organizes exhibitions and conferences in various industries. Reed Elsevier NV was founded in 1903 and is based in Ams terdam, the Netherlands.

Advisors' Opinion:

• [By Vanina Egea]

  Reed Elsevier NV (ENL) is a diversified publisher and information provider. It works on a wide range of market segments that include scientific, technical and medical (STM); legal; risks solutions and business information and exhibitions. The key of the company�� growth, however, lies almost exclusively in two brands: Elsevier and LexisNexis.

Top 10 Regional Bank Stocks To Buy For 2015: Layne Christensen Company(LAYN)

Layne Christensen Company provides drilling, water treatment, and construction services, and related products to water infrastructure and mineral exploration markets. The company?s Water Infrastructure division offers a range of water-related products and services, including soil stabilization, hydrological studies, well design, drilling and development, pump installation, sewer rehabilitation, pipeline construction, and well rehabilitation services; and environmental drilling services to assist in assessing, investigating, monitoring, and characterizing water quality and aquifer parameters. This division also provides water treatment equipment engineering services; systems for the treatment of regulated and nuisance contaminants, such as iron, manganese, hydrogen sulfide, arsenic, radium, nitrate, perchlorate, and volatile organic compounds; wastewater pipeline and structure rehabilitation services; and geotechnical construction services to the heavy civil, industrial, a nd commercial construction markets, as well as designs and constructs water and wastewater treatment plants, and pipeline installations. Its Mineral Exploration division offers exploratory and definitional drilling services for the global mineral exploration industry. The company?s Energy division involves in the acquisition, exploration, development, and production of oil and natural gas primarily in the Midwestern United States. As of January 31, 2011, Layne Christensen Company had approximately 244,000 gross acres under lease and 643 gross producing wells. It also provides energy services. The company offers its services to municipalities, investor-owned water utilities, industrial and mining companies, consulting engineering firms, heavy civil construction contractors, oil and gas companies, and agribusiness. It has operations in North America, Africa, Australia, Europe, and Brazil. Layne Christensen Company was founded in 1981 and is headquartered in Mission Woods, Kan sas.

Advisors' Opinion:

• [By Rich Smith]

  Mission Woods, Kansas-based Layne Christensen (NASDAQ: LAYN  ) has a new Chief Financial Officer.

  On Friday, the heavy construction company announced it has hired former SEH Offshore Ventures CFO, and Seahawk Drilling CEO, James R. Easter to become its own new CFO. A graduate of University of Texas, Austin, with an M.B.A. from the Thunderbird American Graduate School of International Management, Easter will replace outgoing CFO Jerry Fanska, who announced his retirement in December.

Top 10 Regional Bank Stocks To Buy For 2015: Medifocus Inc (MDFZF)

Medifocus Inc.(Medifocus) is a Canada-based company. The Company is engaged in the business of development and commercialization of minimally invasive, focused-heat tumor targeted cancer treatment devices and systems. Medifocus operates through its wholly owned subsidiary, Celsion (Canada) Limited (Celsion). Celsion had purchased from Celsion Corporation (United States), all of the assets relating to breast cancer Microfocus APA 1000 System (System), consisting of the microwave machine, the adaptive phased array (APA) technology licensed from Massachusetts Institute of Technology (MIT). The Company focuses on breast cancer treatment by using microwave heating to enhance neoadjuvant chemotherapy to provide tumor shrinkage and control. Advisors' Opinion:

• [By EquityOptionsGuru]

  Over the past few years, and especially months, biotechnology stocks have been soaring on heightened investor expectations. Investors looking for a unique opportunity to participate in a massive bull rally over the next few years might want to pay special attention to one small but growing company called Medifocus (OTCMKTS:MDFZF).

• [By Peter Graham]

  Small cap stocks KBridge Energy Corp (OTCMKTS: BMMCF), Medifocus Inc (OTCMKTS: MDFZF) and Inscor Inc (OTCMKTS: IOGA) have been getting some attention lately in various investment newsletters and some of it is deserved as the first stock sank 35% on Friday, the second one recently released its financials (which did show a big improvement, but there is also a big catch for investors) and the third one has been the subject of a very aggressive promotional campaign. But are any of these three small caps really all that hot for investors? Here is a quick reality check:

Top 10 Regional Bank Stocks To Buy For 2015: Western Gas Equity Partners LP (WGP)

Western Gas Equity Partners, LP, incorporated on September 11, 2007, was formed to own three types of partnership interests in Western Gas Partners, LP (WES). WES is a limited partnership formed by Anadarko Petroleum Corporation to own, operate, acquire and develop midstream energy assets. As of December 31, 2011, the Company had no independent operations. On January 13, 2012, WES acquired 100% interest of Mountain Gas Resources LLC (MGR). On August 1, 2012, WES acquired 24% interest of Chipeta Processing LLC (Chipeta).

WES is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, natural gas liquids (NGLs) and crude oil for Anadarko, as well as third-party producers and customers. The assets of WGP, through its partnership interests in WES, include thirteen gathering systems, seven natural gas treating facilities, ten natural gas processing facilities, two NGL pipelines, one interstate gas pipeline, one intrastate gas pipeline, and three separate interests in Fort Union, White Cliffs Pipeline, LLC (White Cliffs) and Rendezvous Gas Services, LLC (Rendezvous). These assets are located in East and West Texas, the Rocky Mountains (Colorado, Utah and Wyoming), and the Mid-Continent (Kansas and Oklahoma). WES also has facilities under construction in South Texas and northeast Colorado. During the year ended December 31, 2011, WES completed the construction of a cryogenic processing train at its Chipeta facility , which had a designed capacity of approximately 300 million cubic feet of natural gas per day and was placed into service in October 2012.

Advisors' Opinion:

• [By Jonas Elmerraji]

  The exact same setup is potentially giving traders a reason to jump into shares of $8.5 billion midstream gas company Western Gas Equity Partners (WGP). Just like Flotek, WGP is forming a textbook channel up. And this week, Western Gas is testing trendline support.

  It's a little too early to call WGP's trendline buyable here. At some point, all trends eventually fail -- and when this one does, you don't want to be left holding the bag. A bounce this week will be a good indication that WGP can still catch a bid at this price level. When and if that happens, I'd recommend keeping a tight protective stop in place just below WGP's most recent swing low at $38.

  While the 50-day moving average has been crossing paths with WGP quite a bit in the last month, I'd recommend ignoring it. The average hasn't acted as a meaningful support or resistance level to date. In the case of this particular name, it's just not technically relevant.

Top 10 Regional Bank Stocks To Buy For 2015: IsoRay Inc (ISR)

IsoRay, Inc. (IsoRay), incorporated on June 15, 2004, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. IsoRay obtained clearance from the Food and Drug Association (FDA) for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer, and pancreatic cancer. The seed may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. The Company has an existing distribution agreement with UralDial LLC (UralDial) that allows UralDial to distribute Proxcelan Cs-131 brachytherapy seeds in Russia. The Company, through UralDial, has regulatory approval to sell Cs-131 seeds in Russia.

IsoRay markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; lung cancer; ocular melanoma; head and neck cancers; colorectal cancer, brain cancer; and gynecological cancer. The Company focuses to market Cesium-131 for the treatment of other malignant disease, such as breast cancer, in the near future through the use of existing technologies that have received FDA-clearance. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). When placed into a nuclear reactor and exposed to a flux of neutrons, Ba-130 becomes Ba-131, the radioactive material that is the parent isotope of Cesium-131. The radioactive isotope Cesium-131 is normally produced by placing a quantity of stable non-radioactive barium (ideally barium enriched in isotope Ba-130) into the neutron flux of a nuclear reactor. The irradiation process converts a small fraction of this material into a radioactive form of barium (Ba-131). The Ba-131 decays by electron capture to the ! radioactive isotope of interest (Cesium-131).

As of June 30, 2011, IsoRay had agreements with several independent radiopharmacies to assay, preload, and sterilize loose seeds. During the fiscal year ended June 30, 2011, the Company loaded approximately 90% of Mick cartridges in the Company's own facility, which accounted for approximately 61% of seeds sold. Approximately 33% of seeds sold are strand configurations, including strands preloaded in needles and the remaining 6% of seeds are sold as loose seeds.

Advisors' Opinion:

• [By Vanina Egea]

  Strengthening portfolio and business stability is to be reinforced by the introduction of new products. Last December, Textron announced the successful first flight of the Scorpion Intelligence, Surveillance and Reconnaissance (ISR)/Strike aircraft. ��he Scorpion compares very favorably to more costly aircraft currently used for low-threat missions,��pilot Dan Hinson said. The new product is expected to accommodate the budget constraints and shifting mission requirements of the US Department of Defense. The same department has granted the firm an additional contract worth $22.5 million to "deprocess" Mobile Strike Force vehicles and train the Afghan Army.

• [By James E. Brumley]

  I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).

Top 10 Regional Bank Stocks To Buy For 2015: Icahn Enterprises L.P. (IEP)

Icahn Enterprises L.P., through its subsidiaries, engages in investment, automotive, gaming, railcar, food packaging, metals, real estate, and home fashion businesses in the United States and internationally. Its Investment segment provides investment advisory, and administrative and back office services to the investment funds. The company�s Automotive segment offers powertrain energy, powertrain sealing and bearings, vehicle safety and protection, and aftermarket products for original equipment manufacturers. Icahn Enterprises L.P.�s Gaming segment owns and operates casino gaming properties. It has 9 casino facilities with 7,485 slot machines, 226 table games and 6,048 hotel rooms in Nevada, Mississippi, Indiana, Louisiana, New Jersey, and Aruba. The company�s Railcar segment designs, manufactures, sells, and leases hopper and tank railcars; custom designed railcar parts and other industrial products, primarily aluminum and special alloy steel castings; and provides r epair and maintenance services for railcar fleets. Icahn Enterprises L.P.�s Food Packaging segment produces and sells cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The company�s Metals segment collects, processes, and sells ferrous and non-ferrous metals, as well as processes and distributes steel pipe and plate products. Icahn Enterprises L.P.�s Real Estate segment engages in the rental of retail, office, and industrial properties; construction and sale of single-family and multi-family homes, lots in subdivisions and planned communities, and raw land for residential development; and golf and resort activities. The company�s Home Fashion segment manufactures, sources, distributes, markets, and sells home fashion consumer products, including bed, bath, basic bedding, and kitchen textile products. Icahn Enterprises G.P. Inc. serves as the general partner of the company. Icahn Enterprises L.P. was founded in 1987 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Alex Planes]

  Super investor Carl Icahn of Icahn Enterprises (NASDAQ: IEP  ) has presented his own $15 per-share offer, but this would keep Dell public while Icahn acquired up to 58% of the company's outstanding shares. Icahn already owns 10% of Dell's shares, and Icahn loyalists hold another 5%. He looks poised to raise that stake significantly over the next few trading days: Icahn Enterprises has been cleared to bypass the standard waiting period to raise an investor's stake up to 25%. Icahn now presents a significant roadblock to the Dell buyout, as his long history of activist investing portends a fight for control.